Amelioration of graft versus host disease with anti-ICAM-1 therapy

Lisa Poritz, Michael J. Page, Anna F. Tilberg, Walter Koltun

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We have previously demonstrated an increase in the adhesion molecule lymphocyte function-associated antigen-1 (LFA-1) in GVHD after small bowel transplantation (SBTx) and a therapeutic effect for the monoclonal antibody (MoAb) to LFA-1 in the same model. The present study evaluated the role of MoAb to LFA-1's ligand, intercellular adhesion molecule-1 (ICAM-1) in GVHD. Methods. GVHD was created in LBNF1 rats by heterotopic vascularized SBTx from Lewis donors. Saline treated SBTx-GVHD and sham-operated control animals were compared to animal groups treated with MoAb to ICAM-1 or MoAb to ICAM-1 and LFA-1. GVHD was evaluated by measuring spleen index, white blood cell count, bowel permeability, weight loss, and animal survival. Results. Animals treated with the MoAb to ICAM-1 appeared clinically to have almost as severe GVHD as untreated animals; however, they had improved spleen indices, less neutropenia and weight loss, and survived longer than untreated animals (range 15-22 days in treated animals vs 12-16 days in untreated animals, P < 0.01). Treatment with MoAb to both ICAM-1 and LFA-1 appeared to have a synergistic beneficial effect on GVHD (range 19-29 days, P < 0.001 vs untreated animals). Conclusion. MoAb to ICAM-1 alone or in combination with MoAb to LFA-1 ameliorates GHVD after SBTx and prolongs survival.

Original languageEnglish (US)
Pages (from-to)280-286
Number of pages7
JournalJournal of Surgical Research
Volume80
Issue number2
DOIs
StatePublished - Jan 1 1998

Fingerprint

Graft vs Host Disease
Intercellular Adhesion Molecule-1
Lymphocyte Function-Associated Antigen-1
Monoclonal Antibodies
Therapeutics
Weight Loss
Spleen
Therapeutic Uses
Neutropenia
Leukocyte Count
Permeability
Transplantation
Ligands

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Poritz, Lisa ; Page, Michael J. ; Tilberg, Anna F. ; Koltun, Walter. / Amelioration of graft versus host disease with anti-ICAM-1 therapy. In: Journal of Surgical Research. 1998 ; Vol. 80, No. 2. pp. 280-286.
@article{780294b988e64e8d80475b34e1aee2f1,
title = "Amelioration of graft versus host disease with anti-ICAM-1 therapy",
abstract = "We have previously demonstrated an increase in the adhesion molecule lymphocyte function-associated antigen-1 (LFA-1) in GVHD after small bowel transplantation (SBTx) and a therapeutic effect for the monoclonal antibody (MoAb) to LFA-1 in the same model. The present study evaluated the role of MoAb to LFA-1's ligand, intercellular adhesion molecule-1 (ICAM-1) in GVHD. Methods. GVHD was created in LBNF1 rats by heterotopic vascularized SBTx from Lewis donors. Saline treated SBTx-GVHD and sham-operated control animals were compared to animal groups treated with MoAb to ICAM-1 or MoAb to ICAM-1 and LFA-1. GVHD was evaluated by measuring spleen index, white blood cell count, bowel permeability, weight loss, and animal survival. Results. Animals treated with the MoAb to ICAM-1 appeared clinically to have almost as severe GVHD as untreated animals; however, they had improved spleen indices, less neutropenia and weight loss, and survived longer than untreated animals (range 15-22 days in treated animals vs 12-16 days in untreated animals, P < 0.01). Treatment with MoAb to both ICAM-1 and LFA-1 appeared to have a synergistic beneficial effect on GVHD (range 19-29 days, P < 0.001 vs untreated animals). Conclusion. MoAb to ICAM-1 alone or in combination with MoAb to LFA-1 ameliorates GHVD after SBTx and prolongs survival.",
author = "Lisa Poritz and Page, {Michael J.} and Tilberg, {Anna F.} and Walter Koltun",
year = "1998",
month = "1",
day = "1",
doi = "10.1006/jsre.1998.5422",
language = "English (US)",
volume = "80",
pages = "280--286",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "2",

}

Amelioration of graft versus host disease with anti-ICAM-1 therapy. / Poritz, Lisa; Page, Michael J.; Tilberg, Anna F.; Koltun, Walter.

In: Journal of Surgical Research, Vol. 80, No. 2, 01.01.1998, p. 280-286.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Amelioration of graft versus host disease with anti-ICAM-1 therapy

AU - Poritz, Lisa

AU - Page, Michael J.

AU - Tilberg, Anna F.

AU - Koltun, Walter

PY - 1998/1/1

Y1 - 1998/1/1

N2 - We have previously demonstrated an increase in the adhesion molecule lymphocyte function-associated antigen-1 (LFA-1) in GVHD after small bowel transplantation (SBTx) and a therapeutic effect for the monoclonal antibody (MoAb) to LFA-1 in the same model. The present study evaluated the role of MoAb to LFA-1's ligand, intercellular adhesion molecule-1 (ICAM-1) in GVHD. Methods. GVHD was created in LBNF1 rats by heterotopic vascularized SBTx from Lewis donors. Saline treated SBTx-GVHD and sham-operated control animals were compared to animal groups treated with MoAb to ICAM-1 or MoAb to ICAM-1 and LFA-1. GVHD was evaluated by measuring spleen index, white blood cell count, bowel permeability, weight loss, and animal survival. Results. Animals treated with the MoAb to ICAM-1 appeared clinically to have almost as severe GVHD as untreated animals; however, they had improved spleen indices, less neutropenia and weight loss, and survived longer than untreated animals (range 15-22 days in treated animals vs 12-16 days in untreated animals, P < 0.01). Treatment with MoAb to both ICAM-1 and LFA-1 appeared to have a synergistic beneficial effect on GVHD (range 19-29 days, P < 0.001 vs untreated animals). Conclusion. MoAb to ICAM-1 alone or in combination with MoAb to LFA-1 ameliorates GHVD after SBTx and prolongs survival.

AB - We have previously demonstrated an increase in the adhesion molecule lymphocyte function-associated antigen-1 (LFA-1) in GVHD after small bowel transplantation (SBTx) and a therapeutic effect for the monoclonal antibody (MoAb) to LFA-1 in the same model. The present study evaluated the role of MoAb to LFA-1's ligand, intercellular adhesion molecule-1 (ICAM-1) in GVHD. Methods. GVHD was created in LBNF1 rats by heterotopic vascularized SBTx from Lewis donors. Saline treated SBTx-GVHD and sham-operated control animals were compared to animal groups treated with MoAb to ICAM-1 or MoAb to ICAM-1 and LFA-1. GVHD was evaluated by measuring spleen index, white blood cell count, bowel permeability, weight loss, and animal survival. Results. Animals treated with the MoAb to ICAM-1 appeared clinically to have almost as severe GVHD as untreated animals; however, they had improved spleen indices, less neutropenia and weight loss, and survived longer than untreated animals (range 15-22 days in treated animals vs 12-16 days in untreated animals, P < 0.01). Treatment with MoAb to both ICAM-1 and LFA-1 appeared to have a synergistic beneficial effect on GVHD (range 19-29 days, P < 0.001 vs untreated animals). Conclusion. MoAb to ICAM-1 alone or in combination with MoAb to LFA-1 ameliorates GHVD after SBTx and prolongs survival.

UR - http://www.scopus.com/inward/record.url?scp=0032434774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032434774&partnerID=8YFLogxK

U2 - 10.1006/jsre.1998.5422

DO - 10.1006/jsre.1998.5422

M3 - Article

C2 - 9878325

AN - SCOPUS:0032434774

VL - 80

SP - 280

EP - 286

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 2

ER -